Elena V. Vinnitskaya
Research Subjects
Elena V. Vinnitskaya has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
- Yu. G. Sandler
Loginov Moscow Clinical Scientific Center
10 shared publications - Evgeniia S. Sbikina
Loginov Moscow Clinical Scientific Center
8 shared publications - Kirill Saliev
Loginov Moscow Clinical Scientific and Practical Center
8 shared publications - Tatiana Yu. Khaimenova
Loginov Moscow Clinical Scientific Center
8 shared publications - Dmitriy S. Bordin
Department of Pancreatic, Biliary and Upper Digestive Tract Disorders, A. S. Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia
4 shared publications - Igor Gennadievich Nikitin
N.I. Pirogov Russian National Research Medical University
4 shared publications
Latest Publications
- Open Access
- 5 September 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 24-34
Fixed-Dose Combinations of Glycyrrhizic Acid + Phospholipids and Glycyrrhizic Acid + Ursodeoxycholic Acid in the Treatment of Non-Alcoholic Fatty Liver Disease (Literature Review and Expert Council Resolution)
Aim: to evaluate, based on an analysis of preclinical and clinical data, the efficacy and safety of fixed combinations of glycyrrhizic acid with phospholipids or ursodeoxycholic acid for the treatment of non-alcoholic fatty liver disease. Key points. Glycyrrhizic acid exerts antisteatotic, anti-inflammatory, and antifibrotic effects through the activation of nuclear factor erythroid 2-related factor 2 (Nrf2), the inhibition of sterol regulatory element-binding protein 1c (SREBP-1c), nuclear factor κB (NF-κB), and the modulation of the farnesoid X receptor (FXR)/sirtuin-1 (SIRT1) pathway. The “glycyrrhizic acid + phospholipids” fixed-dose combination (IV for 14 days followed by PO for 10 weeks) is recommended to reduce steatosis and inflammation and to prevent fibrosis (strength of recommendation: B; level of evidence: 2). In clinical studies, a 2–3-month therapy with the drug led to the normalization of aminotransferase activity in the majority of patients, while a 12-month study demonstrated regression of advanced stages of liver fibrosis (F2–F4), up to the complete disappearance of signs of cirrhosis (F4) in all patients. The “glycyrrhizic acid + ursodeoxycholic acid” fixed combination (12 weeks; 15 mg/kg/day of ursodeoxycholic acid) is recommended for patients with non-alcoholic fatty liver disease and elevated aminotransferase levels to reduce inflammation (strength of recommendation: B; level of evidence: 2). Randomized clinical trials have shown more than a twofold reduction in aminotransferase activity, as well as improvements in quality of life. An analysis of more than 1.3 million prescriptions confirms a favorable safety profile for both combinations (overall incidence of adverse events: 0.01–1.4 %, predominantly mild gastrointestinal disturbances). Conclusion. Fixed-dose combinations of “glycyrrhizic acid + phospholipids” and “glycyrrhizic acid + ursodeoxycholic acid” are effective and safe pharmacotherapeutic options for the treatment of non-alcoholic fatty liver disease, exhibiting antisteatotic, anti-inflammatory, and antifibrotic effect as supported by data from randomized clinical trials and post-marketing surveillance in the Russian Federation.
- 5 September 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 24-34
Open AccessFixed-Dose Combinations of Glycyrrhizic Acid + Phospholipids and Glycyrrhizic Acid + Ursodeoxycholic Acid in the Treatment of Non-Alcoholic Fatty Liver Disease (Literature Review and Expert Council Resolution)
Aim: to evaluate, based on an analysis of preclinical and clinical data, the efficacy and safety of fixed combinations of glycyrrhizic acid with phospholipids or ursodeoxycholic acid for the treatment of non-alcoholic fatty liver disease. Key points. Glycyrrhizic acid exerts antisteatotic, anti-inflammatory, and antifibrotic effects through the activation of nuclear factor erythroid 2-related factor 2 (Nrf2), the inhibition of sterol regulatory element-binding protein 1c (SREBP-1c), nuclear factor κB (NF-κB), and the modulation of the farnesoid X receptor (FXR)/sirtuin-1 (SIRT1) pathway. The “glycyrrhizic acid + phospholipids” fixed-dose combination (IV for 14 days followed by PO for 10 weeks) is recommended to reduce steatosis and inflammation and to prevent fibrosis (strength of recommendation: B; level of evidence: 2). In clinical studies, a 2–3-month therapy with the drug led to the normalization of aminotransferase activity in the majority of patients, while a 12-month study demonstrated regression of advanced stages of liver fibrosis (F2–F4), up to the complete disappearance of signs of cirrhosis (F4) in all patients. The “glycyrrhizic acid + ursodeoxycholic acid” fixed combination (12 weeks; 15 mg/kg/day of ursodeoxycholic acid) is recommended for patients with non-alcoholic fatty liver disease and elevated aminotransferase levels to reduce inflammation (strength of recommendation: B; level of evidence: 2). Randomized clinical trials have shown more than a twofold reduction in aminotransferase activity, as well as improvements in quality of life. An analysis of more than 1.3 million prescriptions confirms a favorable safety profile for both combinations (overall incidence of adverse events: 0.01–1.4 %, predominantly mild gastrointestinal disturbances). Conclusion. Fixed-dose combinations of “glycyrrhizic acid + phospholipids” and “glycyrrhizic acid + ursodeoxycholic acid” are effective and safe pharmacotherapeutic options for the treatment of non-alcoholic fatty liver disease, exhibiting antisteatotic, anti-inflammatory, and antifibrotic effect as supported by data from randomized clinical trials and post-marketing surveillance in the Russian Federation.
- Open Access
- 9 June 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (5) , 358-365
Pathogenetic aspects of metabolic dysfunction-associated steatotic liver disease: hyperammonemia and correction options. A review
This review presents the current concept of metabolic dysfunction-associated steatotic liver disease (MASLD) as a systemic disorder, which has replaced the traditional non-alcoholic fatty liver disease model. The prevalence of MASLD reaches 30–40% of the adult population worldwide, and 70–80% in individuals with obesity and type 2 diabetes mellitus. According to projections, by 2030 this disease will become the leading indication for liver transplantation. In the Russian Federation, the prevalence of MASLD is 37.3%, with an increase observed not only in the elderly but also in the young population, creating long-term healthcare system risks. Understanding of the pathogenesis has evolved from the linear “two-hit” model to the concept of multiple parallel-acting factors: adipose tissue dysfunction, chronic inflammation, insulin resistance, lipotoxicity (accumulation of ceramides and diacylglycerols), impaired autophagy, and disturbances in nitrogen metabolism. Particular attention is paid to hyperammonemia, which develops due to epigenetic hypermethylation and p53-mediated suppression of urea cycle enzymes. Ammonia acts as an active pathogenic factor, stimulating the activation of hepatic stellate cells, fibrogenesis, and minimal hepatic encephalopathy already at the pre-cirrhotic stage. A pathogenetically justified correction strategy is the use of L-ornithine-L-aspartate. The drug reduces ammonia levels, restores mitochondrial membrane potential, decreases oxidative stress, improves hepatic microcirculation, and normalizes lipid metabolism. A 2026 systematic review (19 studies, 1671 patients) confirmed the efficacy of L-ornithine-L-aspartate in reducing steatosis, inflammation, and liver fibrosis, as well as in normalizing transaminases and decreasing liver stiffness measured by elastography. For early metabolic support, the combined nutraceutical Hepatostrong® Amino (containing L-ornithine, arginine, methionine, and choline) has been proposed. Its components target three key pathways: ammonia detoxification, lipid metabolism (lipotropic effect), and hepatocyte functional status. The presented data open new perspectives for personalized therapy of MASLD by correcting hyperammonemia as an important driver of disease progression, especially at early stages before cirrhosis develops.
- 9 June 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (5) , 358-365
Open AccessPathogenetic aspects of metabolic dysfunction-associated steatotic liver disease: hyperammonemia and correction options. A review
This review presents the current concept of metabolic dysfunction-associated steatotic liver disease (MASLD) as a systemic disorder, which has replaced the traditional non-alcoholic fatty liver disease model. The prevalence of MASLD reaches 30–40% of the adult population worldwide, and 70–80% in individuals with obesity and type 2 diabetes mellitus. According to projections, by 2030 this disease will become the leading indication for liver transplantation. In the Russian Federation, the prevalence of MASLD is 37.3%, with an increase observed not only in the elderly but also in the young population, creating long-term healthcare system risks. Understanding of the pathogenesis has evolved from the linear “two-hit” model to the concept of multiple parallel-acting factors: adipose tissue dysfunction, chronic inflammation, insulin resistance, lipotoxicity (accumulation of ceramides and diacylglycerols), impaired autophagy, and disturbances in nitrogen metabolism. Particular attention is paid to hyperammonemia, which develops due to epigenetic hypermethylation and p53-mediated suppression of urea cycle enzymes. Ammonia acts as an active pathogenic factor, stimulating the activation of hepatic stellate cells, fibrogenesis, and minimal hepatic encephalopathy already at the pre-cirrhotic stage. A pathogenetically justified correction strategy is the use of L-ornithine-L-aspartate. The drug reduces ammonia levels, restores mitochondrial membrane potential, decreases oxidative stress, improves hepatic microcirculation, and normalizes lipid metabolism. A 2026 systematic review (19 studies, 1671 patients) confirmed the efficacy of L-ornithine-L-aspartate in reducing steatosis, inflammation, and liver fibrosis, as well as in normalizing transaminases and decreasing liver stiffness measured by elastography. For early metabolic support, the combined nutraceutical Hepatostrong® Amino (containing L-ornithine, arginine, methionine, and choline) has been proposed. Its components target three key pathways: ammonia detoxification, lipid metabolism (lipotropic effect), and hepatocyte functional status. The presented data open new perspectives for personalized therapy of MASLD by correcting hyperammonemia as an important driver of disease progression, especially at early stages before cirrhosis develops.
- 10 April 2026
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 4
Sarcopenia in patients with non-alcoholic fatty liver disease: pathogenesis, diagnosis and treatment (expert opinion)
Introduction. Currently, sarcopenia, a disease characterized by a decrease in muscle mass, strength, and function, is increasingly being detected in clinical practice by physicians of various specialties. Sarcopenia is most often diagnosed in elderly and senile individuals, but can also develop in middle-aged and young individuals as a result of various diseases. A number of studies demonstrate the association of sarcopenia with non-alcoholic fatty liver disease (NAFLD). To date, issues of diagnosis and treatment of sarcopenia in routine clinical practice in patients with NAFLD, as well as the impact of sarcopenia therapy on the prevention of complications and progression of NAFLD, remain unresolved. Methodology. The Scientific Society of Gastroenterologists of Russia (SSGR) brought together 12 experts in the field of studying sarcopenia and NAFLD to make reasoned statements and recommendations on the issue of «Sarcopenia in patients with non-alcoholic fatty liver disease: pathogenesis, diagnosis and treatment». An extended literature search of articles in English was conducted using the keywords - sarcopenia, classification of sarcopenia, phenotypes and pathogenesis of sarcopenia, modern diagnostic methods and potential non-drug (rational nutrition and physical activity) and therapeutic methods for correcting sarcopenia, non-alcoholic fatty liver disease in the following international databases: PubMed, Google Scholar, Web of Science, Embase, Cochrane Database, search for ongoing relevant studies - on the ClinicalTrials.gov website. An extended literature search was carried out in Russian in the databases: electronic resource «Clinical Guidelines Rubricator of the Ministry of Health of the Russian Federation», eLibrary, RusMed. According to the information received, the text is structured into separate chapters. Each chapter contains key provisions (expert opinion) on the relevant section and the currently available data concerning a particular section. The authors present tables, expert conclusions and a list of modern literature devoted to sarcopenia and its phenotypes. Results (by key provisions). The experts worked to identify the most significant issues on the given topic, formulated questions relevant to clinical practice and gave reasoned answers to them, presented as «provisions» for clinical practice with comments based on evidence-based medicine. The formulation of questions, recommendations and provisions is based on a critical analysis of medical literature in English and Russian language databases. The results of the expert work are directly related to the quality management of patients with sarcopenia and NAFLD, and the key provisions they formulated can be used in clinical practice. Conclusions. The document presented by the expert group «Sarcopenia in patients with non-alcoholic fatty liver disease: pathogenesis, diagnosis and treatment» is intended to help practicing physicians improve their knowledge of the problem of sarcopenia and learn how to diagnose the syndrome early in routine clinical practice, and not only in patients of older age groups, but also in young and middle-aged patients, in whom sarcopenia develops as a consequence of chronic diseases.
- 10 April 2026
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 4
Sarcopenia in patients with non-alcoholic fatty liver disease: pathogenesis, diagnosis and treatment (expert opinion)
Introduction. Currently, sarcopenia, a disease characterized by a decrease in muscle mass, strength, and function, is increasingly being detected in clinical practice by physicians of various specialties. Sarcopenia is most often diagnosed in elderly and senile individuals, but can also develop in middle-aged and young individuals as a result of various diseases. A number of studies demonstrate the association of sarcopenia with non-alcoholic fatty liver disease (NAFLD). To date, issues of diagnosis and treatment of sarcopenia in routine clinical practice in patients with NAFLD, as well as the impact of sarcopenia therapy on the prevention of complications and progression of NAFLD, remain unresolved. Methodology. The Scientific Society of Gastroenterologists of Russia (SSGR) brought together 12 experts in the field of studying sarcopenia and NAFLD to make reasoned statements and recommendations on the issue of «Sarcopenia in patients with non-alcoholic fatty liver disease: pathogenesis, diagnosis and treatment». An extended literature search of articles in English was conducted using the keywords - sarcopenia, classification of sarcopenia, phenotypes and pathogenesis of sarcopenia, modern diagnostic methods and potential non-drug (rational nutrition and physical activity) and therapeutic methods for correcting sarcopenia, non-alcoholic fatty liver disease in the following international databases: PubMed, Google Scholar, Web of Science, Embase, Cochrane Database, search for ongoing relevant studies - on the ClinicalTrials.gov website. An extended literature search was carried out in Russian in the databases: electronic resource «Clinical Guidelines Rubricator of the Ministry of Health of the Russian Federation», eLibrary, RusMed. According to the information received, the text is structured into separate chapters. Each chapter contains key provisions (expert opinion) on the relevant section and the currently available data concerning a particular section. The authors present tables, expert conclusions and a list of modern literature devoted to sarcopenia and its phenotypes. Results (by key provisions). The experts worked to identify the most significant issues on the given topic, formulated questions relevant to clinical practice and gave reasoned answers to them, presented as «provisions» for clinical practice with comments based on evidence-based medicine. The formulation of questions, recommendations and provisions is based on a critical analysis of medical literature in English and Russian language databases. The results of the expert work are directly related to the quality management of patients with sarcopenia and NAFLD, and the key provisions they formulated can be used in clinical practice. Conclusions. The document presented by the expert group «Sarcopenia in patients with non-alcoholic fatty liver disease: pathogenesis, diagnosis and treatment» is intended to help practicing physicians improve their knowledge of the problem of sarcopenia and learn how to diagnose the syndrome early in routine clinical practice, and not only in patients of older age groups, but also in young and middle-aged patients, in whom sarcopenia develops as a consequence of chronic diseases.
- Open Access
- 7 March 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (2) , 119-124
A new paradigm of the pathogenesis of primary sclerosing cholangitis associated with ulcerative colitis: microbiota and system intestine-liver. A review
The close relationship between primary sclerosing cholangitis and ulcerative colitis has given rise to a number of hypotheses aimed at deciphering their pathogenesis from the standpoint of bidirectional connections involving immune, endocrine and inflammatory mechanisms. The review examines the main directions of the concept of the "gut-liver axis" from the point of view of the pathogenetic relationships of primary sclerosing cholangitis associated with ulcerative colitis and intestinal microbiota.
- 7 March 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (2) , 119-124
Open AccessA new paradigm of the pathogenesis of primary sclerosing cholangitis associated with ulcerative colitis: microbiota and system intestine-liver. A review
The close relationship between primary sclerosing cholangitis and ulcerative colitis has given rise to a number of hypotheses aimed at deciphering their pathogenesis from the standpoint of bidirectional connections involving immune, endocrine and inflammatory mechanisms. The review examines the main directions of the concept of the "gut-liver axis" from the point of view of the pathogenetic relationships of primary sclerosing cholangitis associated with ulcerative colitis and intestinal microbiota.
- Open Access
- 25 June 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (2) , 105-118
Occurrence of Alleles of the HLA-A/B/C/DPB1/DQB1/DRB1 Genes in Autoimmune Hepatitis (Results of a Single-Center Study)
Aim: determination of alleles of HLA genes associated with autoimmune hepatitis (AIH) and overlap syndrome (OS) in the Russian population.Materials and methods. The study included 160 adult patients with a verified diagnosis of AIH or OS. The control group consisted of 320 conditionally healthy participants. A custom NGS panel was used to type the alleles of the HLA class I and II genes. The statistical analysis was carried out using Pearson’s χ2 test with multiple FDR correction (p < 0.05). A logistic regression model was used to evaluate HLA alleles as predictors of the disease.Results. Alleles and haplotypes which frequencies have statistically significant difference in the study and control groups were identified. In the study group, alleles HLA-A*01:01:01 (OR = 2.15; 95 % CI: 1.43–3.23), HLA-B*08:01:01 (OR = 3.38; 95 % CI: 2.10–5.44), HLA-C*07:01:01 (OR = 1.90; 95 % CI: 1.30–2.78), HLA-DPB1*01:01:01 (OR = 3.22; 95 % CI: 1.58–6.55), DQB1*02:01:01 (OR = 3.11; 95 % CI: 2.06–4.70), HLA-DRB1*03:01:01 (OR = 3.03; 95 % CI: 2.02–4.55) were more common. Frequency of occurrence of the DQB1*03:01:01 allele in the study group was lower than in the control group (OR = 0.49; 95 % CI: 0.34–0.71). A logistic regression model was built, which was characterized by an accuracy of 0.688, a sensitivity of 0.487, and a specificity of 0.887.Conclusion. Alleles and haplotypes of HLA genes associated with AIH and OS were identified in a representative sample of the Russian population.
- 25 June 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (2) , 105-118
Open AccessOccurrence of Alleles of the HLA-A/B/C/DPB1/DQB1/DRB1 Genes in Autoimmune Hepatitis (Results of a Single-Center Study)
Aim: determination of alleles of HLA genes associated with autoimmune hepatitis (AIH) and overlap syndrome (OS) in the Russian population.Materials and methods. The study included 160 adult patients with a verified diagnosis of AIH or OS. The control group consisted of 320 conditionally healthy participants. A custom NGS panel was used to type the alleles of the HLA class I and II genes. The statistical analysis was carried out using Pearson’s χ2 test with multiple FDR correction (p < 0.05). A logistic regression model was used to evaluate HLA alleles as predictors of the disease.Results. Alleles and haplotypes which frequencies have statistically significant difference in the study and control groups were identified. In the study group, alleles HLA-A*01:01:01 (OR = 2.15; 95 % CI: 1.43–3.23), HLA-B*08:01:01 (OR = 3.38; 95 % CI: 2.10–5.44), HLA-C*07:01:01 (OR = 1.90; 95 % CI: 1.30–2.78), HLA-DPB1*01:01:01 (OR = 3.22; 95 % CI: 1.58–6.55), DQB1*02:01:01 (OR = 3.11; 95 % CI: 2.06–4.70), HLA-DRB1*03:01:01 (OR = 3.03; 95 % CI: 2.02–4.55) were more common. Frequency of occurrence of the DQB1*03:01:01 allele in the study group was lower than in the control group (OR = 0.49; 95 % CI: 0.34–0.71). A logistic regression model was built, which was characterized by an accuracy of 0.688, a sensitivity of 0.487, and a specificity of 0.887.Conclusion. Alleles and haplotypes of HLA genes associated with AIH and OS were identified in a representative sample of the Russian population.
- Open Access
- 18 June 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 8,p. 17-23
Materials of the expert council on the topic “Morpholinium thiosate: From mechanisms of action to clinical practice. Optimization of clinical application”
The publication presents the findings of a multidisciplinary expert council convened to analyze data from clinical studies on morpholinium thiazotate (thiotriazoline) conducted with a focus on cardiovascular and liver disease, as well as their comorbidities. Thiotriazoline’s mechanism of action is based on its ability to mitigate oxidative stress by modulating NO synthase activity, improve endothelial function, and exert anti-inflammatory effects. Clinical studies have demonstrated its efficacy in treating cardiovascular diseases, liver disorders, and their combined presentations. Of particular interest is its potential as an adjunct therapy in oncology and phthisiopulmonology where cardiotoxicity and hepatotoxicity pose significant challenges. The expert council evaluated the available research and outlined key recommendations for thiotriazoline’s clinical use and further investigation. The drug can be recommended as either a primary or adjunctive therapy for: cardiovascular diseases (stable angina pectoris II– III functional class, chronic heart failure, drug-induced cardiotoxicity); combined liver and cardiovascular disorders, including non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and metabolic dysfunctionassociated liver injury (MET-ABP); reducing cardioand hepatotoxicity in oncology and antituberculosis treatмent. To strengthen the evidence base, further methodologically rigorous clinical trials are needed.
- 18 June 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 8,p. 17-23
Open AccessMaterials of the expert council on the topic “Morpholinium thiosate: From mechanisms of action to clinical practice. Optimization of clinical application”
The publication presents the findings of a multidisciplinary expert council convened to analyze data from clinical studies on morpholinium thiazotate (thiotriazoline) conducted with a focus on cardiovascular and liver disease, as well as their comorbidities. Thiotriazoline’s mechanism of action is based on its ability to mitigate oxidative stress by modulating NO synthase activity, improve endothelial function, and exert anti-inflammatory effects. Clinical studies have demonstrated its efficacy in treating cardiovascular diseases, liver disorders, and their combined presentations. Of particular interest is its potential as an adjunct therapy in oncology and phthisiopulmonology where cardiotoxicity and hepatotoxicity pose significant challenges. The expert council evaluated the available research and outlined key recommendations for thiotriazoline’s clinical use and further investigation. The drug can be recommended as either a primary or adjunctive therapy for: cardiovascular diseases (stable angina pectoris II– III functional class, chronic heart failure, drug-induced cardiotoxicity); combined liver and cardiovascular disorders, including non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and metabolic dysfunctionassociated liver injury (MET-ABP); reducing cardioand hepatotoxicity in oncology and antituberculosis treatмent. To strengthen the evidence base, further methodologically rigorous clinical trials are needed.
- Open Access
- 9 March 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (1) , 94-152
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with non-alcoholic fatty liver disease, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of nonalcoholic fatty liver disease, peculiarities of its clinical course. Also given recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for nonalcoholic fatty liver disease and its clinical phenotypes assessment, approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician's actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with nonalcoholic fatty liver disease contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.
- 9 March 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (1) , 94-152
Open AccessClinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with non-alcoholic fatty liver disease, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of nonalcoholic fatty liver disease, peculiarities of its clinical course. Also given recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for nonalcoholic fatty liver disease and its clinical phenotypes assessment, approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician's actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with nonalcoholic fatty liver disease contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.
- Open Access
- 30 December 2024
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 34 (6) , 100-119
Diagnosis and Treatment of Patients with Autoimmune Hepatitis (Experts’ Agreement)
Background. In the last decade, the understanding of the pathogenesis of autoimmune hepatitis (AIH) has significantly deepened, based on the results of new clinical studies some diagnostic issues have been revised and immunosuppressive therapy regimens have been optimized.Materials and methods. The latest Russian clinical guidelines for the diagnosis and treatment of AIH were presented in 2013; and in 2017, the first Russian agreement on the diagnosis and treatment of AIH was held. Updating approaches to the management of patients with AIH necessitated next systematization for use in clinical practice. In February 2024, the final session was held to discuss the provisions of the second agreement on the diagnosis and treatment of AIH.Results. This publication presents the main discussion points of the agreement regarding methods and algorithms for detecting autoantibodies, the role of liver biopsy, revised morphological criteria for AIH, optimized immunosuppressive therapy regimens, updated criteria for assessing the response to therapy.Conclusions. The agreement was the result of the work of a group of experts on the diagnosis and treatment of AIH and represents the basis for the creation of updated federal clinical guidelines.
- 30 December 2024
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 34 (6) , 100-119
Open AccessDiagnosis and Treatment of Patients with Autoimmune Hepatitis (Experts’ Agreement)
Background. In the last decade, the understanding of the pathogenesis of autoimmune hepatitis (AIH) has significantly deepened, based on the results of new clinical studies some diagnostic issues have been revised and immunosuppressive therapy regimens have been optimized.Materials and methods. The latest Russian clinical guidelines for the diagnosis and treatment of AIH were presented in 2013; and in 2017, the first Russian agreement on the diagnosis and treatment of AIH was held. Updating approaches to the management of patients with AIH necessitated next systematization for use in clinical practice. In February 2024, the final session was held to discuss the provisions of the second agreement on the diagnosis and treatment of AIH.Results. This publication presents the main discussion points of the agreement regarding methods and algorithms for detecting autoantibodies, the role of liver biopsy, revised morphological criteria for AIH, optimized immunosuppressive therapy regimens, updated criteria for assessing the response to therapy.Conclusions. The agreement was the result of the work of a group of experts on the diagnosis and treatment of AIH and represents the basis for the creation of updated federal clinical guidelines.
- 8 October 2024
- Published by Medforum in Effective Pharmacotherapy
- Vol. 20 (30)
Lysosomal Acid Lipase Deficiency under the Mask of NAFLD: a Clinical Case of Primary Diagnosis in a 47-Year-Old Man
Lysosomal acid lipase deficiency (DLK) is an autosomal recessive disease caused by mutations in the LIPA gene. Cholesterol ester accumulation disease (BNEH) is a clinical phenotype of DLCL characterized by lysosomal acid lipase (LCL) activity with residual enzymatic activity of 1–5%, manifested at a later age and characterized by slow progression (unlike the main classical phenotype of DLCL – Wolman's disease). As a rule, even with histological examination of the liver, such patients may be diagnosed with non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) or cryptogenic liver disease. The use of recombinant human sebelipase alpha as a replacement therapy opens up opportunities for long-term and successful treatment of patients with DLKL. The presented clinical case illustrates the possibilities of diagnosing this rare disease, hidden under the mask of NAFLD and first identified at the age of 47 years.
- 8 October 2024
- Published by Medforum in Effective Pharmacotherapy
- Vol. 20 (30)
Lysosomal Acid Lipase Deficiency under the Mask of NAFLD: a Clinical Case of Primary Diagnosis in a 47-Year-Old Man
Lysosomal acid lipase deficiency (DLK) is an autosomal recessive disease caused by mutations in the LIPA gene. Cholesterol ester accumulation disease (BNEH) is a clinical phenotype of DLCL characterized by lysosomal acid lipase (LCL) activity with residual enzymatic activity of 1–5%, manifested at a later age and characterized by slow progression (unlike the main classical phenotype of DLCL – Wolman's disease). As a rule, even with histological examination of the liver, such patients may be diagnosed with non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) or cryptogenic liver disease. The use of recombinant human sebelipase alpha as a replacement therapy opens up opportunities for long-term and successful treatment of patients with DLKL. The presented clinical case illustrates the possibilities of diagnosing this rare disease, hidden under the mask of NAFLD and first identified at the age of 47 years.
- Open Access
- 30 March 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (2) , 107-116
Efficacy of human placenta hydrolyzate in the treatment of patients with metabolic associated fatty liver disease at the stage of fibrosis (pilot study)
Background. Despite active research, drug treatment options for metabolic associated fatty liver disease (MAFLD) are limited, and there are no currently approved drugs for patients with MAFLD. Treatment of patients at risk of developing non-alcoholic steatohepatitis and progressive liver fibrosis (LF) is of particular relevance, since they determine the clinical outcomes of the disease. Aim. To evaluate the clinical efficacy of complex polypeptide drug (CPD), human placenta hydrolyzate, containing low molecular weight regulatory peptides, amino acids, vitamins, macro- and microelements in patients with MAFLD at the LF stage. Materials and methods. A single-center, placebo-controlled pilot study. Patients with MAFLD at LF stage 1≤F≤3 according to METAVIR were included (n=10, of which 8 were women, median age was 55 years old). Patients were randomized into 2 groups: 5 people received CPD therapy for 12 weeks (intravenous infusion of 6 ml 2 times a week); another 5 people initially received placebo x 2 times a week (12 weeks), with transfer to the open phase for CPD therapy in the same regimen. The dynamics laboratory and instrumental data was assessed, as well as determine the presence of fibrosis by non-invasive tests – measurement of liver stiffness by transient elastography and use of serum biomarker (SM) by FibroTest and detection of steatosis with controlled attenuation parameter for transient elastography and SM by SteatoTest. The quality of life of patients was assessed using questionnaire SF-36 and well-being via Visual Analogue Scale. Statistical processing of the material was carried out using the methods of nonparametric analysis, using the Statistica 13.3 software. Results. Patients in the CPD group compared with the baseline data and with the placebo group showed a statistically significant improvement: 1) transaminases (ALT, AST), lipid profile indicators (cholesterol), ferritin; 2) indicators of LF, based on a decrease in liver stiffness by transient elastography and SM of Fibrotest, as well as the degree of steatosis based on controlled attenuation parameter and SM of Steatotest; 3) in well-being and quality of life (according to testing: SF-36 physical, mental well-being and general condition of the VAS). CPD was well tolerated, no side effects were noted. Conclusion. In patients with MAFLD during CPD therapy, a decrease in the level of liver enzymes was noted, as well as in LF and liver steatosis according to noninvasive methods. Randomized controlled trials are required to confirm these findings.
- 30 March 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (2) , 107-116
Open AccessEfficacy of human placenta hydrolyzate in the treatment of patients with metabolic associated fatty liver disease at the stage of fibrosis (pilot study)
Background. Despite active research, drug treatment options for metabolic associated fatty liver disease (MAFLD) are limited, and there are no currently approved drugs for patients with MAFLD. Treatment of patients at risk of developing non-alcoholic steatohepatitis and progressive liver fibrosis (LF) is of particular relevance, since they determine the clinical outcomes of the disease. Aim. To evaluate the clinical efficacy of complex polypeptide drug (CPD), human placenta hydrolyzate, containing low molecular weight regulatory peptides, amino acids, vitamins, macro- and microelements in patients with MAFLD at the LF stage. Materials and methods. A single-center, placebo-controlled pilot study. Patients with MAFLD at LF stage 1≤F≤3 according to METAVIR were included (n=10, of which 8 were women, median age was 55 years old). Patients were randomized into 2 groups: 5 people received CPD therapy for 12 weeks (intravenous infusion of 6 ml 2 times a week); another 5 people initially received placebo x 2 times a week (12 weeks), with transfer to the open phase for CPD therapy in the same regimen. The dynamics laboratory and instrumental data was assessed, as well as determine the presence of fibrosis by non-invasive tests – measurement of liver stiffness by transient elastography and use of serum biomarker (SM) by FibroTest and detection of steatosis with controlled attenuation parameter for transient elastography and SM by SteatoTest. The quality of life of patients was assessed using questionnaire SF-36 and well-being via Visual Analogue Scale. Statistical processing of the material was carried out using the methods of nonparametric analysis, using the Statistica 13.3 software. Results. Patients in the CPD group compared with the baseline data and with the placebo group showed a statistically significant improvement: 1) transaminases (ALT, AST), lipid profile indicators (cholesterol), ferritin; 2) indicators of LF, based on a decrease in liver stiffness by transient elastography and SM of Fibrotest, as well as the degree of steatosis based on controlled attenuation parameter and SM of Steatotest; 3) in well-being and quality of life (according to testing: SF-36 physical, mental well-being and general condition of the VAS). CPD was well tolerated, no side effects were noted. Conclusion. In patients with MAFLD during CPD therapy, a decrease in the level of liver enzymes was noted, as well as in LF and liver steatosis according to noninvasive methods. Randomized controlled trials are required to confirm these findings.